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Abstract
Background—Psychostimulants improve a variety of cognitive/behavioral processes in patients
with attention deficit hyperactivity disorder (ADHD). Limited observations suggest a potentially
different dose-sensitivity of prefrontal cortex (PFC)-dependent function (narrow inverted-U-
shaped dose-response curves) vs. classroom/overt behavior (broad inverted-U) in children with
ADHD. Recent work in rodents observed that methylphenidate (MPH; Ritalin®) elicits a narrow
inverted-U shaped improvement in performance in PFC-dependent tests of working memory. The
current studies first tested the hypothesis that PFC-dependent tasks, in general, display narrow
dose sensitivity to the beneficial actions of MPH.
Methods—The effects of varying doses of MPH were examined on performance of rats in two
tests of PFC-dependent cognition, sustained attention and attentional set shifting. Additionally, the
effect of pretreatment with the α1-antagonist, prazosin (0.5 mg/kg), on MPH-induced
improvement in sustained attention was examined.
Results—MPH produced a broad inverted-U-shaped facilitation of sustained attention and
attentional set shifting. Prior research indicates α1-receptors impair, while α2-receptors improve,
working memory. In contrast, attentional set shifting is improved with α1-receptor activation,
while α2-receptors exert minimal effects in this task. Given the similar dose sensitivity of
sustained attention and attentional set shifting tasks, additional studies examined whether α1-
receptors promote sustained attention, similar to attentional set shifting. In these studies MPH-
induced improvement in sustained attention was abolished by α1-receptor blockade.
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Conclusions—PFC-dependent processes display differential sensitivity to the cognition-
enhancing actions of psychostimulants that are linked to the differential involvement of α1- vs. α2-
receptors in these processes. These observations have significant preclinical and clinical
implications.
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ADHD; Prefrontal Cortex; Cognition; Methylphenidate; Norepinephrine; Dopamine
Psychostimulants exert behavioral-calming and cognition-enhancing actions in the treatment
of attention deficit hyperactivity disorder (ADHD). In laboratory testing, clinical doses of
psychostimulants improve a variety of behavioral and cognitive processes dependent on the
prefrontal cortex (PFC) in ADHD subjects (1). Moreover, these effects are not unique to
ADHD, with similar actions observed in normal human and animal subjects, provided low
and clinically-relevant doses are used (2–5).
Early studies by Sprague and Sleator reported that in children with ADHD, methylphenidate
(MPH, Ritalin®) produced a narrow inverted-U shaped facilitation of performance in a
laboratory-based test of ‘cognition/learning’, while classroom behavior was improved across
a wider range of doses (6). However, subsequent studies generally failed to observe
differential dose sensitivity across a variety of cognitive and behavioral tests in ADHD
patients (for review, 7–9). A potentially important factor in this work is that the cognitive
task utilized by Sprague and Sleator involved short-term memory testing across short delays
(seconds), typical of tests used to assess PFC-dependent working memory (6). Moreover,
MPH also produced a narrow inverted-U shaped improvement in a PFC-dependent test of
response inhibition in ADHD patients which differed from a generally linear dose-dependent
improvement in overt behavior (9). Combined, these observations suggest the hypothesis
that psychostimulants exert differential dose-dependent effects on PFC-dependent vs. PFC-
independent processes.
In rats and monkeys, MPH elicits a narrow inverted-U-shaped facilitation of performance in
PFC-dependent delayed-response tests of working memory (4, 5, 10–13). Sustained
attention is also dependent on the PFC (14) and in an earlier study, MPH improved
performance of rats in a signal detection test of sustained attention at a dose that maximally
improved working memory performance (0.5 mg/kg; 4). The current studies tested the
hypothesis that differing PFC-dependent processes display similar restricted dose sensitivity
to psychostimulants. These studies first examined whether the dose-dependent actions of
MPH on sustained attention are comparable to those seen in tests of working memory.
Surprisingly, MPH produced a broader and right-shifted inverted-U shaped facilitation of
sustained attention relative to that seen with working memory testing. To assess whether this
broader inverted-U curve is limited to focused, relatively inflexible attention, additional
studies examined the dose-dependent effects of MPH in a PFC-dependent attentional set
shifting task, that requires attentional shifts to previously irrelevant stimuli (15, 16). In this
task, MPH also produced a broad inverted-U shaped facilitation of performance, virtually
identical to that seen in sustained attention testing.
Noradrenergic α1-receptors are known to impair performance in tests of working memory
while α2-receptors promote performance and contribute to the beneficial effects of MPH in
these tests (17). In contrast, α1-receptors improve attentional set shifting while α2-receptors
have little impact in this test (18). These observations suggest that the narrow vs. broad
inverted-U shaped actions of psychostimulants may involve differential actions of α2- vs. α1-
receptors, respectively. Currently, the role of α1-receptors in sustained attention is not
known. Thus, additional studies examined the effects of pretreatment with the α1-antagonist,
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prazosin (0.5 mg/kg), on MPH-induced improvements in sustained attention. These studies
demonstrate that α1-receptor blockade completely prevents the beneficial effects of MPH on
sustained attention.
Combined with earlier observations, these studies demonstrate that distinct PFC-dependent
cognitive processes differ in their dose sensitivity to the cognition-enhancing actions of
psychostimulants. This difference in sensitivity to psychostimulants is associated with
differential actions of noradrenergic α2- vs. α1-receptors across these processes.
METHODS
MPH Dose-Response Curve in the Signal Detection Test of Sustained Attention (Madison,
WI)
Subjects—7 male Sprague-Dawley rats (290–370 g, Harlan, Madison, WI) were housed
2–3/cage on a 12-hr light/dark cycle. Care and testing of animals was in accordance with
federal and university animal care guidelines.
Testing Procedures—Body weight was reduced to 85% of ad libitum weight while water
was provided ad libitum. Animals were trained and tested in an operant-based signal
detection test of sustained attention previously described (19; see also 20). Briefly, on one
half of the trials (selected at random, p = 0.5) an LED was illuminated and two levers were
projected into the chamber (“Signal Trials”). The signal length was variable, randomly
selected from the list: 0.125, 0.25, 0.5, 0.75, 1.0, 1.5, and 2.0-sec with replacement. On the
other half of the trials, the LED remained dark, after which both levers were inserted (“No
Signal Trials”). The levers remained in the chamber until a response was made, at which
time both levers were retracted. On signal trials, a right lever press was scored as a ‘Hit’ and
reinforced with two sucrose pellets (45 mg pellets, Dustless Precision Pellets, Bio-Serv,
Frenchtown, NJ) while a left lever press was scored as a “miss”. On a no signal trial, a right
lever press was scored as a “false alarm”. A left lever press on a no-signal trial was
reinforced with 2 pellets (“correct rejection”). For all correct response trials, the house lights
were illuminated for 5-sec with reward presentation. For all incorrect trials, the levers were
retracted and a 5-sec time-out period ensued (houselights off). Failure to respond within 5-
sec of lever insertion, the levers were retracted, followed by a 5-sec blackout. A variable
inter-trial interval of 13-sec (minimum 5-sec), on average, elapsed before the start of new
trial. Trials with no response occurred infrequently and were excluded from analyses. Single
trials lasted about 20-sec and all sessions lasted for 100 trials. Animals were trained until
proportion of correct trials reached 75%–85%.
MPH testing occurred in a three-arm design. Each arm consisted of either “low”, “medium”,
or “high” doses of MPH with vehicle (normal saline) treatment included in each arm and
each dose replicated 3 times per arm. Treatments were randomized within an arm. The first
arm consisted of 0.5 mg/kg and 2.0 mg/kg MPH, doses that define the inverted-U shaped
dose response curve for working memory testing. Based on unexpected results obtained in
the first arm, the second arm consisted of 2.0 mg/kg (to replicate the first arm) and 4.0 mg/
kg MPH. Finally, the third arm utilized 8.0 mg/kg MPH. All treatments were delivered IP
30-min prior to testing. Dependent measures include the proportion of trials with a correct
response (proportion of hits + proportion of correct rejections), the probability of a hit
(number of right responses/number of signal trials), probability of a false alarm (number of
right responses/number of no signal trials), c (response bias), and d′, a relative measure of
stimulus detectability (d′ = Z(N) − Z(SN). Z(N) = Z-score of the Noise Distribution = Z-
score of (1−probability of false alarms). Z(SN) = Z-score of the Signal + Noise distribution
= Z-score of 1−probability of a hit). d′ takes into account both the probability of a hit and
the probability of a false alarm (see 21).
Berridge et al. Page 3













MPH Dose-Response Curve in Attentional Set Shifting (Durham, NH)
Subjects—12 male Sprague Dawley rats (275–300 g, Charles River, Wilmington, MA)
were subjected to food restriction (18 gms) and allowed ad libitum access to water and
housed on a 12-hr light cycle.
Testing Procedures—All training and testing was as described previously (22). Briefly,
rats were trained to dig in pots for food reinforcers (45 mg food pellet, Dustless Precision
Pellets, Bio-serv, Frenchtown, NJ) until they successfully retrieved 10 buried reinforcers. On
the following day, rats began exemplar training on three simple discriminations of texture,
odor or digging media. Rats were then tested on a simple discrimination, compound
discrimination and reversal to facilitate formation of an attentional set (e.g. focus attention
on odor). Animals were then tested on an intradimensional shift (IDS), where a novel set of
stimuli is introduced but the attribute that predicts reward remains the same (e.g. odor).
After the successful completion of six consecutive IDS trials, a reinforcement reversal was
performed (IDR), where the alternate odor from the testing pair was reinforced. We next
tested for extradimensional attentional set shifts (EDS), which involved reinforcing a
previously unattended dimension, (e.g. if odor had previously been reinforced, digging
material is then reinforced). After successful completion of the EDS, a final reversal (EDR)
of the session occurred (e.g. the alternate digging media in the pair predicts reward).
Animals were treated IP with either vehicle or varying doses of 0.5 mg/kg, 2.0 mg/kg, and
4.0 mg/kg MPH 15-minutes prior to IDS testing. The number of trials to reach criterion
performance level of six consecutive correct trials was recorded for IDS, EDS, IDR and
EDR.
α1-Receptor Action in a Signal Detection Test of Sustained Attention Task (Philadelphia,
PA)
Subjects—Six male Sprague Dawley Rats (150–176g, Taconic, Germantown, PA) were
trained in an operant-based signal detection task of sustained attention (12-hr light cycle).
Animals were water restricted, receiving 10-min free drink in their home cage after testing
(~20 ml).
Testing Procedures—Testing and apparatus were similar to that described above, with
the following exceptions. Hits and Correct Rejections resulted in the delivery of 40 μl water.
On signal trials, rats were trained to respond to a short duration (15-msec) light. Testing
occurred daily over 45-min and rats received equal numbers of randomly presented signal
and non-signal trials. Criterion performance required a rat to achieve greater than 59%
signal and non-signal trials and less than 25% omissions per day for three consecutive days.
Rats were treated IP with vehicle (saline), MPH (0.5 mg/kg, 2.0 mg/kg, 3.5 mg/kg), 0.5 mg/
kg of the α1-antagonist, prazosin, or 0.5 mg/kg prazosin + 2.0 mg/kg MPH. Prazosin was
administered IP 15-min before MPH and 35-min prior to testing. For the prazosin studies,
animals were first prescreened for sensitivity to MPH. The ~85% of animals that showed
improvement with MPH were used for these studies.
Statistical Analysis
Sustained Attention MPH Dose-Response—Repeated-measures ANOVA with
planned comparisons were used to determine the degree to which MPH treatment differed
from vehicle treatment.
Attentional set shifting—ANOVA was used to assess treatment effects on attentional set
shifting and reversal trials. The number of trials needed to reach criterion performance in the
ID was compared to the ED using a within-subjects ANOVA with Dose (4 levels) and Test
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(ID vs. ED; 2 levels) as factors. In a series of planned comparisons, the effects of MPH on
ID and ED were compared to those of vehicle. A separate repeated-measures ANOVA with
Test (2 levels, IDR and EDR) and Dose (4 levels) was used to determine the effects of MPH
on the number of trials to reach criterion on reversal learning. One rat failed to engage in
testing following drug administration and was excluded from the analysis.
α1-Antagonist + MPH in Sustained Attention—Repeated-measures ANOVA with
planned comparisons was used to assess treatment effects on sustained attention
performance relative to baseline performance (4 levels: baseline, MPH, prazosin, MPH +
prazosin) and to compare the effects of MPH to those of prazosin and MPH + prazosin.
RESULTS
MPH Exerts a Broad Inverted-U Shaped Facilitation of Sustained Attention
We first examined whether sustained attention is improved by MPH across the same dose
range observed previously for working memory in our laboratory (4). Animals (n=7) were
treated with vehicle or varying doses of MPH (0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg, 8.0 mg/kg)
30-min prior to sustained attention testing as described above.
These studies demonstrate that MPH facilitates sustained attention, as measured by the
change in d′ from baseline, in an inverted-U shaped manner (see Figure 1A and Table 1; arm
1, F2,12=6.12, p=0.015; arm 2, F2,12=6.02, p=0.015; arm 3, F1,6=20.01, p=0.004). Planned
comparisons indicated that, as observed previously (4), 0.5 mg/kg MPH increased d′ relative
to vehicle treatment (t6=3.40, p<0.007). In contrast to that seen in working memory testing,
2.0 mg/kg MPH further improved sustained attention as measured by d′ (arm 1, t6=3.07, p =
0.01). This effect of 2.0 mg/kg MPH was replicated in the second testing arm (F2, 12=6.02,
p=0.015; vehicle vs. 2.0 mg/kg, t6=5.53, p<0.001). This beneficial effect of MPH decreased
with increasing dose such that 4.0 mg/kg did not significantly alter (t6=1.20, p=0.14) while
8.0 mg/kg MPH significantly reduced d′ (t6=−4.48, p=0.002).
As shown in Table 1, a virtually identical pattern was observed for most other measures of
performance. Thus, probability of a hit was increased with 2.0 mg/kg MPH (F2, 12=7.57, p<
0.01; t6=3.71, p=0.004), with a strong trend for improvement at 0.5 mg/kg (t6=1.77, p=0.06).
This effect of 2.0 mg/kg MPH was generally replicated in arm 2 testing (F2,12=1.40, p=0.29;
t6=1.93, p=0.051). As with d′, 4.0 mg/kg did not alter while 8.0 mg/kg reduced the
probability of a hit (t6=−2.34, p=0.03). MPH significantly affected the proportion of correct
trials (arm 1, F2,12=5.51, p=0.02; arm 2, F2,12=3.15, p=0.08; arm 3, F1,6=14.81, p=0.008)
with improvement seen at 0.5 mg/kg (t6 = 2.96, p = 0.012) and 2.0 mg/kg (arm 1, t6=2.84,
p=0.015; arm 2, t6=3.35, p=0.007), no effect at 4.0 mg/kg (t6=−0.10, p=0.46) and a decrease
in this measure at 8.0 mg/kg (t6=−3.85, p=0.004). MPH had less consistent effects on
probability of false alarms (arm 1, F2,12=1.40, p=0.29; arm 2, F2,12=3.16, p= 0.08; arm 3;
F1,6=0.67, p=0.44).
The above-described results were obtained in Madison, WI. Similar studies were conducted
in Philadelphia, PA, where the effects of 0.5 mg/kg, 2.0 mg/kg and 3.5 mg/kg MPH (n = 6)
were examined. These studies obtained nearly identical inverted-U dose-dependent effects
of MPH on sustained attention, with maximal improvement in performance at 2.0 mg/kg
MPH (see Table II; F1,5=1.55, p=0.27; t5=−3.37, p=0.02). The one difference observed
across the two laboratories is that the 0.5 mg/kg dose of MPH did not significantly improve
performance in these latter studies. This could be related to the fact that the shorter signal
duration used in the Philadelphia laboratory appears to make the task more perceptually-
challenging (d′ of saline-treated animals, Madison, WI = 2.1 ± 0.1; d′ of saline-treated
animals, Philadelphia, PA = 0.6 ± 0.2) and thus possibly more dependent on the perceptual
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actions of methylphenidate, which largely occur at higher doses, including 2.0 mg/kg (see
23, 24). Additionally, Madison testing utilized 3 replications of each treatment, likely
reducing variability in treatment effects.
MPH Exerts a Broad Inverted-U Shaped Facilitation of Extradimensional Attentional Set
shifting
To determine whether the broader inverted-U dose response curve is unique to sustained
attention, we examined the effects of MPH on attentional set shifting, a task that requires
shifting of attention across intra- and extradimensional cues (Figure 2). The number of trials
to reach criterion performance in the intradimensional shift was significantly lower than on
the extradimensional shift (F1,30=26.18, p<0.001), indicating that shifting attention set is
more difficult than maintaining attention set. All subjects required more trials to reach
criterion performance on extradimensional reversals than intradimensional reversals (see
Figure 2; F1,10=7.20, p=0.02). Planned comparisons demonstrated that 2.0 mg/kg MPH
facilitated extradimensional shifts relative to vehicle treatment (t10=3.21, p=0.009). No other
dose of MPH produced a significant change in extradimensional shifts (all p>0.32). MPH
did not significantly affect intradimensional shifts (all p>0.19) or reversals (Dose:
F3,30=0.37, p=0.78; Test × Dose F3,30=1.25, p=0.31).
α1-Receptor Activation is Necessary for the Facilitatory Effects of MPH on Sustained
Attention
Prior studies demonstrate that attentional set shifting is facilitated by α1-receptor stimulation
while α2-receptors facilitate working memory (18). Given similar actions of MPH on
attentional set shifting and sustained attention, we hypothesized that α1-receptors may
facilitate sustained attention, similar to attentional set shifting, and that this action of α1-
receptors may contribute to the beneficial effects of MPH on sustained attention. Thus, the
effects of pretreatment with the α1-antagonist, prazosin (0.5 mg/kg), on MPH (2.0 mg/kg)-
induced improvement in sustained attention were examined (n=14). Animals were treated
with either MPH, prazosin, or combined treatment with prazosin + MPH. ANOVA indicated
a significant effect of treatment on performance relative to baseline (F3,39=4.01, p=0.01). As
shown in Figure 3, 2.0 mg/kg MPH once again significantly improved sustained attention
relative to baseline (t13=3.60, p<0.01) while prazosin alone did not affect sustained attention
(t13=0.79, p=0.45). However, prazosin pretreatment completely blocked the beneficial
effects of 2.0 mg/kg MPH, leaving performance indistinguishable from baseline (t13=0.16,
p=0.87).
DISCUSSION
At clinically-relevant doses, psychostimulants improve a variety of PFC-dependent
processes in ADHD patients as well as normal human and animal subjects (1, 9, 25). In
humans, monkeys and rats, MPH elicits a narrow inverted-U-shaped improvement in PFC-
dependent working memory and response inhibition (4, 5, 6, 9, 12, 25). However, the
current studies demonstrate that the narrow inverted-U-shaped action of MPH is not
universally observed across all PFC-dependent tasks. Specifically, in two additional tests of
PFC-dependent cognition, sustained attention and attentional set shifting, MPH produced
beneficial actions across a broader and/or higher dose range than seen in tests of working
memory. Importantly, the differential dose sensitivity across tasks does not reflect a
differential dependency on the PFC as inactivation/lesion of this area dramatically impairs
performance in all of these tasks (15, 16). In particular, we recently observed that temporary
inactivation of the medial PFC of rats decreases performance to chance levels in both
working memory and sustained attention tasks (unpublished observations, RC Spencer and
CW Berridge).
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The narrow vs. broad/right-shifted dose-response curves observed in our studies are
strikingly similar to those described in children with ADHD across PFC-dependent working
memory/response inhibition tests (narrow) vs. overt behavior (broad; 6, 9). Moreover, a
similar pattern in dose sensitivity to psychostimulants has been observed in preliminary
studies in monkeys tested in a delayed-response task of working memory (narrow) vs. the
ability of the animal to stay focused and engaged in the task (broad; 11). These observations
indicate distinct PFC-dependent cognitive/behavioral processes vary in sensitivity to
psychostimulant dose. The fact that these differing actions of MPH across tasks have been
documented within and across laboratories as well as across species adds significant strength
to this conclusion (see above, 4, 5, 10–13, 6).
Receptor and circuit mechanisms underlying differential dose sensitivity to
psychostimulants
These studies further provide the first evidence that differences in sensitivity to
psychostimulants across PFC-dependent tasks involve differential actions of noradrenergic
α2- and α1-receptors. For example, an extensive body of work demonstrates that
noradrenergic α1-receptor activation within the PFC impairs, while activation of
postsynaptic α2-receptors improves working memory performance. Consistent with this, α2-
receptor blockade prevents MPH-induced improvement in tests of working memory (5).
However, a very different pattern of α1- vs. α2-receptor action is observed in attentional
tasks that display broad/right-shifted dose-dependent actions of MPH. Specifically, prior
work demonstrates that α1-receptors within the PFC facilitate attentional set shifting (in the
absence of MPH), while α2-receptor activation fails to alter performance in this task (18).
The current observations indicate a similar beneficial action of α1-receptors in sustained
attention. Moreover, these observations demonstrate that α1-receptor activation is necessary
for MPH-induced improvement in sustained attention. Although it remains unknown
whether α1-receptors are necessary for MPH-induced improvement in attentional set-shifting
remains, prior observations provide strong support for this hypothesis (18). Moreover,
regardless of whether α1-receptors are necessary for MPH-induced improvement in
attentional set shifting, it is clear that differing modulatory actions of α1- vs. α2-receptors on
performance across these tasks are associated with differing sensitivity to psychostimulants.
Clinically-relevant doses of MPH that maximally improve working memory performance
produce a relatively selective elevation of extracellular catecholamines within the PFC,
while modestly higher doses affect extracellular catecholamine levels more broadly within
the brain (19). Thus, the broader/right-shifted inverted-U curves seen in the sustained
attention and attentional set shifting tasks could also reflect actions of MPH on
catecholamine signaling in regions outside the PFC. In this regard, it is of interest that higher
doses of MPH were observed to increase responsiveness of weakly responding neurons in
somatosensory cortex (24), similar to that seen with α1-agonists (26). Therefore, the
beneficial effect of higher doses of MPH on attentional processes may involve drug-induced
alterations in α1-receptor signaling in posterior cortical regions. Clinically, the simultaneous
targeting of α1-receptors in posterior cortices and PFC-promoting α2-receptors may explain
why simultaneous treatment with α2A agonists and psychostimulants can be more
efficacious than either treatment alone in some patients with ADHD (27). Moreover,
attention- and/or sensory-related actions of α1-receptors may have implications for disorders
outside ADHD, including post-traumatic stress disorder, which is associated with
hypervigilance and treated pharmacologically with α1-antagonists (28, 29).
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What Cognitive Processes Are Involved in the Differential Dose Sensitivity to
Psychostimulants?
The cognitive processes that underlie the differential dose sensitivity across tasks are not
clear. All of the tests used to study the cognitive/behavioral effects of low-dose
psychostimulants require a variety of perceptual, cognitive and motivational processes. The
current results indicate that the divergence of dose-response curves across PFC-dependent
tasks cannot simply be ascribed to ‘focused’ vs. ‘flexible’ cognition given higher doses
improved performance in both sustained attention (focused) and the attentional set shifting
tasks (flexible). However, recent studies in monkeys demonstrate that at a dose of that
improves focused attention, MPH impaired both working memory performance and a form
of task switching involving suppression of prepotent responses, similar to tests of response
inhibition (9, 11, 30). These observations suggest that tasks associated with narrow inverted-
U shaped dose response curves may involve specific form(s) of cognitive flexibility and/or
response inhibition. Further research is needed to identify the cognitive/behavioral processes
that contribute to differing dose sensitivity of these tasks to low-dose psychostimulants.
Preclinical and Clinical Implications—Preclinically, the current observations raise the
question of whether a subset of PFC-dependent cognitive tasks is more relevant for drug
discovery programs focused on ADHD. Extensive evidence demonstrates that the
pharmacology of delayed-response tests of working memory is in close alignment with the
pharmacology of ADHD. Specifically, performance in these tasks is improved by all
approved ADHD-related drugs, including α2A agonists (31), low-dose psychostimulants (25)
and selective NE reuptake blockers (e.g. atomoxetine; 12). Moreover, at least in the case of
psychostimulants, beneficial effects on working memory performance only occur across a
narrow dose range that produce clinically-relevant plasma concentrations (11, 19, 31–34).
Lastly, working memory performance of rats and monkeys is impaired by stressors known
to impair PFC-dependent cognition in humans (e.g. Stroop test; 13, 35). These observations
indicate that delayed response tests of working memory are a suitable preclinical tool for
identifying potentially efficacious compounds for use in ADHD and other clinical conditions
associated with PFC dysfunction (e.g. stress).
In contrast, in the sustained attention and attentional set shifting tasks, MPH facilitates
performance at doses that produce plasma concentrations in rats estimated to exceed the
clinically-relevant range (19, 33). Additionally, limited observations indicate that α2-
agonists lack beneficial effects on attentional set shifting (18) as well as sustained attention
(unpublished observations, JL Berkowitz, BD Waterhouse, JS Shumsky). Thus, the potential
utility of these tests in a preclinical program focused on the pharmacology of ADHD is less
clear. Further pharmacological research is needed to definitively address this issue.
Clinically, and as suggested by Sprague and Sleator (6) and Tannock and colleagues (9), the
current results raise the question of whether doses that are optimal for controlling classroom
behavior impair, or no longer improve, cognitive/behavioral processes important for other
domains of academic and/or social functioning. For example, largely anecdotal evidence has
suggested that psychostimulant treatment of ADHD can result in cognitive constriction or
over-focusing (for review, 9). Such an action may be related to the ability of higher doses of
MPH to improve attention while impairing certain forms of cognitive flexibility (9, 30). If
so, the current results could suggest the use of α1-antagonists as a potential adjunct treatment
for ADHD. Additional clinical studies are needed to better understand how the actions of
differing doses of psychostimulants across differing tests of PFC-dependent cognition relate
to clinical, social, and academic outcomes and the degree to which α1-receptors participate
in adverse or beneficial clinical actions of psychostimulants and other drugs used in the
treatment of ADHD.
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MPH exerts a broad inverted-U dose-dependent improvement in performance in a sustained
attention test. Panel A: Shown are the effects of varying doses of MPH on performance in a
signal detection test of sustained attention as measured by change in d′ from baseline
performance (Madison, WI testing; Triangles, left axis). Relative to vehicle treatment (Veh)
0.5 mg/kg MPH significantly improved performance, consistent with our previous
observations (4). 2.0 mg/kg MPH produced an even larger improvement in performance in
this task while 4.0 mg/kg MPH did not improve and 8.0 mg/kg MPH significantly impaired
performance. The breadth of this dose response curve differs from that seen in a delayed
response task of spatial working memory (Squares, right axis; data from 10). For working
memory testing, animals were required to alternate arm entries following a delay (10–120
seconds) that yielded 70–80% accurate performance. MPH produces a substantially
narrower inverted-U shaped facilitation of working memory performance than seen in the
sustained attention task, with maximal improvement occurring at 0.5 mg/kg and impairment
at 2.0 mg/kg. Panel B: Effects of varying doses of MPH on sustained attention as tested in
Philadelphia, PA. Despite significant differences in testing procedures and baseline levels of
performance (see Methods and Results) nearly identical dose-response effects of MPH on
sustained attention were obtained to those shown in Panel A, with maximal improvement in
performance occurring at 2.0 mg/kg. In particular, the magnitude of the increase in d′ seen
with this dose of MPH was nearly identical across the two laboratories. *P < 0.05; **P <
0.01 relative to vehicle treatment.
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Dose-dependent improvement in attentional set shifting by MPH is similar to that seen in
sustained attention testing. Shown are the effects of varying doses of MPH (0.5 mg/kg, 2.0
mg/kg and 4.0 mg/kg) on intradimensional (IDS) and extradimensional (EDS) tests. As
shown in the top panel, MPH significantly improved EDS as indicated by the reduction in
the number of trials needed to reach criterion performance on this test of attentional set
shifting. Similar to that seen in the sustained attention task, maximal facilitation (as
indicated by the number of trials to reach criterion) was observed at 2.0 mg/kg (IP), but not
4.0 mg/kg. There was no effect of the drug on the formation of the attentional set (bottom
graph). *P < 0.05; **P < 0.01 relative to vehicle treatment.
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α1-receptor blockade prevents MPH-induced improvement in sustained attention. Animals
were treated with either: 1) 2.0 mg/kg MPH; 2) 0.5 mg/kg of the α1-receptor antagonist,
prazosin; 3) 0.5 mg/kg prazosin + 2.0 mg/kg MPH. Shown are values for d′, expressed as a
change from baseline. 2.0 mg/kg MPH improved performance in this task, similar to that
seen in Figure 1. Treatment with prazosin had no effect on sustained attention performance.
In contrast, this dose of prazosin completely blocked the facilitating effects of MPH on
sustained attention. **P < 0.01 vs. baseline; +P < 0.05 vs. vehicle.
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